NRX Pharmaceuticals Inc
NRXP2.370USD
+0.190+8.72%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
65.61MMarket Cap
LossP/E TTM
More Details of NRX Pharmaceuticals Inc Company
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
NRX Pharmaceuticals Inc Info
Ticker SymbolNRXP
Company nameNRX Pharmaceuticals Inc
IPO dateNov 20, 2017
CEOJavitt (Jonathan C)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endNov 20
Address1201 Orange Street
CityWILMINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19801
Phone14842546134
Websitehttps://www.nrxpharma.com/
Ticker SymbolNRXP
IPO dateNov 20, 2017
CEOJavitt (Jonathan C)
Company Executives of NRX Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan C. Javitt, M.D.
Dr. Jonathan C. Javitt, M.D.
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
1.52M
-0.01%
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
221.48K
--
Mr. Michael (Mike) Taylor
Mr. Michael (Mike) Taylor
Independent Director
Independent Director
--
--
Mr. Patrick J. Flynn
Mr. Patrick J. Flynn
Independent Director
Independent Director
--
--
Mr. Riccardo (Rick) Panicucci
Mr. Riccardo (Rick) Panicucci
Chief Manufacturing and Technology Officer
Chief Manufacturing and Technology Officer
--
--
Mr. Michael S. (Mike) Abrams
Mr. Michael S. (Mike) Abrams
Chief Financial Officer and Treasurer
Chief Financial Officer and Treasurer
--
--
Dr. Dennis Mcbride
Dr. Dennis Mcbride
Independent Director
Independent Director
--
--
Mr. Matthew P. Duffy
Mr. Matthew P. Duffy
Chief Business Officer
Chief Business Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan C. Javitt, M.D.
Dr. Jonathan C. Javitt, M.D.
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
1.52M
-0.01%
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
221.48K
--
Mr. Michael (Mike) Taylor
Mr. Michael (Mike) Taylor
Independent Director
Independent Director
--
--
Mr. Patrick J. Flynn
Mr. Patrick J. Flynn
Independent Director
Independent Director
--
--
Mr. Riccardo (Rick) Panicucci
Mr. Riccardo (Rick) Panicucci
Chief Manufacturing and Technology Officer
Chief Manufacturing and Technology Officer
--
--
Mr. Michael S. (Mike) Abrams
Mr. Michael S. (Mike) Abrams
Chief Financial Officer and Treasurer
Chief Financial Officer and Treasurer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
B Group, Inc.
10.68%
Anson Funds Management LP.
7.21%
Javitt (Jonathan C)
5.40%
Glytech LLC
3.43%
The Vanguard Group, Inc.
1.90%
Other
71.38%
Shareholders
Shareholders
Proportion
B Group, Inc.
10.68%
Anson Funds Management LP.
7.21%
Javitt (Jonathan C)
5.40%
Glytech LLC
3.43%
The Vanguard Group, Inc.
1.90%
Other
71.38%
Shareholder Types
Shareholders
Proportion
Investment Advisor
15.18%
Hedge Fund
7.85%
Individual Investor
6.34%
Corporation
3.43%
Investment Advisor/Hedge Fund
1.72%
Research Firm
0.31%
Other
65.16%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
66
6.31M
26.53%
+3.75M
2025Q2
66
5.07M
29.31%
+1.44M
2025Q1
66
4.06M
26.08%
+505.82K
2024Q4
70
3.94M
22.32%
-356.61K
2024Q3
83
3.57M
28.23%
-628.46K
2024Q2
86
3.38M
32.03%
-634.67K
2024Q1
92
3.27M
34.30%
-835.14K
2023Q4
98
3.31M
81.28%
-805.62K
2023Q3
101
3.31M
42.19%
-663.76K
2023Q2
103
3.89M
52.92%
+527.79K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
B Group, Inc.
3.00M
12.62%
+3.00M
--
Aug 18, 2025
Anson Funds Management LP.
1.60M
6.75%
+425.91K
+36.12%
Jun 30, 2025
Javitt (Jonathan C)
1.52M
6.38%
-199.00
-0.01%
Apr 29, 2025
Glytech LLC
963.48K
4.05%
+963.48K
--
Apr 29, 2025
The Vanguard Group, Inc.
452.18K
1.9%
+63.25K
+16.26%
Jun 30, 2025
AdvisorShares Investments, LLC
263.80K
1.11%
-23.00K
-8.02%
Jun 30, 2025
Hurvitz (Chaim)
221.48K
0.93%
+1.00
+0.00%
Apr 29, 2025
Marshall Wace LLP
33.38K
0.14%
-55.70K
-62.53%
Jun 30, 2025
Geode Capital Management, L.L.C.
172.25K
0.72%
+37.60K
+27.92%
Jun 30, 2025
UBS Financial Services, Inc.
121.61K
0.51%
+121.50K
+115717.14%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
6.62%
iShares Micro-Cap ETF
0.01%
AdvisorShares Psychedelics ETF
Proportion6.62%
iShares Micro-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
Date
Type
Ratio
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
FAQs
Who are the top five shareholders of NRX Pharmaceuticals Inc?
The top five shareholders of NRX Pharmaceuticals Inc are:
B Group, Inc. holds 3.00M shares, accounting for 12.62% of the total shares.
Anson Funds Management LP. holds 1.60M shares, accounting for 6.75% of the total shares.
Javitt (Jonathan C) holds 1.52M shares, accounting for 6.38% of the total shares.
Glytech LLC holds 963.48K shares, accounting for 4.05% of the total shares.
The Vanguard Group, Inc. holds 452.18K shares, accounting for 1.90% of the total shares.
B Group, Inc. holds 3.00M shares, accounting for 12.62% of the total shares.
Anson Funds Management LP. holds 1.60M shares, accounting for 6.75% of the total shares.
Javitt (Jonathan C) holds 1.52M shares, accounting for 6.38% of the total shares.
Glytech LLC holds 963.48K shares, accounting for 4.05% of the total shares.
The Vanguard Group, Inc. holds 452.18K shares, accounting for 1.90% of the total shares.
What are the top three shareholder types of NRX Pharmaceuticals Inc?
The top three shareholder types of NRX Pharmaceuticals Inc are:
B Group, Inc.
Anson Funds Management LP.
Javitt (Jonathan C)
B Group, Inc.
Anson Funds Management LP.
Javitt (Jonathan C)
How many institutions hold shares of NRX Pharmaceuticals Inc (NRXP)?
As of 2025Q3, 66 institutions hold shares of NRX Pharmaceuticals Inc, with a combined market value of approximately 6.31M, accounting for 26.53% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -2.78%.
What is the biggest source of revenue for NRX Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for NRX Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
